ESMO 2023 | Barriers to complex biomolecular testing in Europe

Arnaud Bayle, MD, Gustave Roussy, Villejuif, France, discusses barriers that prevent access to complex multi-gene biomolecular testing in comparison to simple testing across Europe. As expected, cost plays a major role here in terms of testing and/or treatment reimbursement. Additionally, the availability of a suitable medicine or clinical trial enrolment and communication to both clinicians and patients regarding this impacts the uptake of these tests. This could be improved through access to molecular tumour boards (MTBs) and knowledge of ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), for example. There are also issues related to testing organisations, including result turnover. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.